Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Core Insights - Biomea Fusion, Inc. is developing BMF-219, an investigational oral covalent menin inhibitor aimed at regenerating insulin-producing beta cells for diabetes treatment [1][6] - The company will present data from its Phase II clinical trials, COVALENT-111 and COVALENT-112, at the ATTD-ASIA 2024 conference in Singapore [1][3] Group 1: Clinical Trials - COVALENT-111 is a Phase I/II study focusing on type 2 diabetes, involving approximately 200 patients who completed their dosing period before the FDA placed the study on hold [4] - COVALENT-112 is a Phase II study for adults with stage 3 type 1 diabetes, enrolling around 150 patients, with an open-label portion for adults diagnosed up to 15 years [5] Group 2: Presentation Details - The presentations will include a long oral presentation on COVALENT-112 and two short oral presentations on COVALENT-111, scheduled for November 19-20, 2024 [3] - The late breaker presentation will focus on case studies assessing BMF-219 in patients with poorly controlled severe insulin-deficient type 2 diabetes [1][3] Group 3: Company Overview - Biomea Fusion specializes in discovering and developing oral covalent small molecules for treating metabolic diseases and genetically defined cancers [6] - The company utilizes its proprietary FUSION™ System to enhance the development of next-generation covalent-binding small molecule medicines [7]